Chicago is a city that moves fast — from long workdays downtown to evenings spent at Cubs or White Sox games, cheering on the Blackhawks, catching a Bulls matchup, or enjoying neighborhood street festivals and concerts. For many residents, keeping weight under control in a city full of year-round temptations is a challenge. Injectco – PRP Treatment Clinic offers Retatrutide injections through a physician-supervised program designed to help you lose weight effectively while fitting into your lifestyle.
Why Chicago patients choose us: Free consultations – in-person or virtual (telehealth appointments available until 8:30 PM every night); Same-day prescription shipping anywhere in Illinois, with signature-required delivery available upon request; Licensed nurses & nurse practitioners under MD supervision; Customized programs with ongoing monitoring.
Retatrutide, developed by Eli Lilly, is an advanced triple-mechanism peptide in late-stage clinical trials. In a study published in The New England Journal of Medicine, participants lost up to 24.2% of their body weight in 48 weeks.
We work with patients throughout the city and suburbs, including:
Whether you live near the Loop, along the lakefront, or in the western suburbs, our program is available in person or via telehealth with discreet shipping to your door.
Our city has its own unique factors that affect weight loss:
Our Retatrutide program is designed to work in all seasons — keeping you on track from January snow to summer street fests and afternoons at Wrigley Field.
Many Chicagoans have heard of Semaglutide (Ozempic®, Wegovy®) or Tirzepatide (Mounjaro®, Zepbound®). Retatrutide builds on these with an additional mechanism for even stronger results.
| Medication | GLP‑1 Activation | GIP Activation | Glucagon Activation | Avg. Weight Loss (48 wks) |
|---|---|---|---|---|
| Semaglutide | ✅ | ❌ | ❌ | ~15% |
| Tirzepatide | ✅ | ✅ | ❌ | ~21% |
| Retatrutide | ✅ | ✅ | ✅ | ~24% |
By activating GLP‑1, GIP, and glucagon receptors, Retatrutide helps reduce appetite, improve blood sugar balance, and increase fat metabolism simultaneously.
Retatrutide is a synthetic peptide that mimics natural gut hormones to:
This triple-action approach is why early research shows stronger average results than other GLP‑1-based treatments.
You may be a candidate if you:
When you schedule your consultation, you can choose in-person or virtual. During the visit:
If approved, we ship your medication the same day in discreet packaging, with signature confirmation available if you prefer.
We use a step-up dosing protocol to maximize results and minimize side effects:
Month 1
Appetite begins to decrease; smaller portions feel natural.
Months 2–3
Steady weight loss; more energy for daily activities, commuting, or catching a Hawks game after work.
Months 4–6
Significant body composition changes; improved stamina for summer runs along the Lakefront Trail.
6+ Months
Transition to maintenance phase with sustainable habits.
Clinical trial averages show:
Common temporary side effects include:
These usually lessen after the first few weeks. Our medical team monitors you throughout treatment.
Our program includes:
Pricing depends on dosage and program length. Visit prptreatmentclinic.com or call our Chicago office for a quote.
Retatrutide is an investigational metabolic medication designed to influence multiple hormone pathways involved in appetite regulation, blood sugar balance, and energy expenditure. It is classified as a triple agonist, meaning it activates three metabolic receptors that play a role in weight regulation.
By addressing hunger signaling and metabolic function simultaneously, Retatrutide is being studied as a structured medical weight management option. Treatment decisions are always made under licensed medical supervision and individualized based on patient health history.
Availability depends on current regulatory status and clinical program access. In Chicago, medical weight loss programs may evaluate patients for emerging metabolic therapies when clinically appropriate.
A consultation with a licensed provider is required to determine eligibility and review current treatment options. Not all patients qualify, and medical clearance is necessary prior to beginning therapy.
Clinical studies have demonstrated significant percentage-based weight reduction in participants using Retatrutide alongside lifestyle modifications. Outcomes vary depending on metabolic health, starting weight, adherence, and individualized treatment planning.
Weight management is approached as a medical process rather than a short-term solution. Ongoing provider monitoring ensures progress is measured safely and adjustments are made when clinically indicated.
Retatrutide targets three hormone receptors involved in metabolic regulation. In comparison, Semaglutide primarily targets GLP-1, while Tirzepatide targets both GLP-1 and GIP receptors.
The additional metabolic pathway may enhance appetite and energy regulation in certain patients. However, medication selection depends on individual health history, tolerance, and provider evaluation.
Adults with a BMI in the overweight or obesity range who have struggled with sustainable weight loss may be evaluated for treatment. Candidates are typically those who have not achieved desired results with lifestyle adjustments alone.
A full medical assessment is required prior to prescribing. Individual factors such as cardiovascular health, endocrine conditions, medication use, and overall risk profile are reviewed carefully.
Reported side effects in clinical research have included nausea, gastrointestinal discomfort, decreased appetite, and mild digestive changes. These symptoms are often temporary and may improve with dose adjustment.
All metabolic medications require medical monitoring. Patients are educated on potential risks, warning signs, and follow-up protocols to ensure safety throughout treatment.
Treatment duration varies depending on individual goals and clinical response. Medical weight loss therapies are typically integrated into a structured program that includes monitoring, nutrition guidance, and long-term planning.
Continuation is evaluated on a case-by-case basis. The focus remains on metabolic health stabilization and sustainable results rather than rapid weight reduction.
Pricing varies depending on dosage, monitoring requirements, and whether treatment is part of a comprehensive medical weight management plan. Costs are discussed during consultation after eligibility is determined.
Because this therapy requires prescription oversight, individualized evaluation is necessary before providing final treatment recommendations.
Yes. Retatrutide is a prescription-based metabolic medication and must be prescribed by a licensed medical provider. It is not available over the counter.
Clinical supervision ensures appropriate dosing, medical screening, and ongoing monitoring for safety and effectiveness.
Retatrutide is being studied for its impact on metabolic regulation, including blood glucose control and insulin sensitivity. Research suggests it may support improved metabolic markers alongside weight reduction.
However, patients with diabetes or endocrine conditions require coordinated medical management. Treatment decisions are individualized and based on full clinical evaluation.
